Anti-IgE treatment of eosinophil-associated gastrointestinal disorders.

ABSTRACT:

Background

Eosinophil-associated gastrointestinal disorders (EGIDs) are commonly associated with atopy and are being recognized with increasing frequency. Current therapy for EGIDs is inadequate.

Objective

We sought to determine the efficacy of anti-IgE therapy in EGIDs and investigate the role of IgE in disease pathogenesis.

Methods

Nine subjects with EGIDs received omalizumab every 2 weeks for 16 weeks while other therapy was held constant. Blood absolute eosinophil counts, tissue eosinophil counts, symptom scores, and free IgE levels were serially measured. Allergen skin testing and flow cytometry for basophil activation and FcepsilonRI were determined at baseline and at week 16.

Results

Omalizumab was associated with a decrease in absolute eosinophil count

SUBMITTER: Foroughi S 

PROVIDER: S-EPMC2768344 | biostudies-literature | 2007 Sep

REPOSITORIES: biostudies-literature